BioCryst Pharmaceuticals Financial Ratios
NASDAQ: BCRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
8.55+0.26 (+3.14%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BioCryst Pharmaceuticals ratio analysis
BioCryst Pharmaceuticals earned a net margin of 30.2% in FY 2025, up from -19.7% a year earlier. Gross margin was 97.8% compared with a median of 95.4% over the prior 8 years. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
BioCryst Pharmaceuticals financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 6.20 | — | — | — | — | — | — | — | — | — |
| Price / sales | 1.80 | 3.53 | 3.47 | 7.88 | 15.78 | 69.96 | — | — | — | — |
| Gross margin | 97.8% | 97.3% | 98.6% | 97.6% | 95.4% | 91.3% | 92.4% | — | 95.5% | 91.3% |
| Operating margin | 39.0% | -0.6% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | -227.9% | -184.4% |
| Net margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1,026.4% | -223.0% | -490.3% | -261.2% | -209.3% |
| Free cash flow margin | 39.4% | -11.8% | -29.4% | -60.3% | -92.0% | -761.4% | -184.1% | -450.0% | -164.7% | -222.8% |
| Return on equity (ROE) | — | — | — | — | — | — | -284.7% | -205.7% | -78.5% | -3,494.6% |
| Return on assets (ROA) | 51.3% | -18.1% | -43.8% | -44.9% | -31.3% | -54.6% | -62.1% | -69.0% | -36.9% | -61.4% |
| Debt / equity | — | — | — | — | — | — | 0.00 | 0.61 | 0.27 | 14.58 |
| Current ratio | 2.06 | 2.63 | 3.31 | 4.90 | 5.46 | 3.06 | 1.78 | 1.65 | 1.68 | 1.23 |
| Revenue growth | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% | -63.5% | 136.5% | -18.0% | -4.4% | -45.4% |